Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions
about
Trazodone and omeprazole interaction causing frequent second-degree Mobitz type 1 atrioventricular (AV) block (Wenckebach phenomenon) and syncope: a case report and literature reviewFluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4Omeprazole increases the efficacy of a soluble epoxide hydrolase inhibitor in a PGE₂ induced pain modelAn S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator.Cytochrome P450 induction properties of food and herbal-derived compounds using a novel multiplex RT-qPCR in vitro assay, a drug-food interaction prediction toolPrediction of gestational age-dependent induction of in vivo hepatic CYP3A activity based on HepaRG cells and human hepatocytes.The CYP2C19 Intron 2 Branch Point SNP is the Ancestral Polymorphism Contributing to the Poor Metabolizer Phenotype in Livers with CYP2C19*35 and CYP2C19*2 Alleles.Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase contentRETRACTED: CYP2D6 Is Inducible by Endogenous and Exogenous CorticosteroidsUse of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator.Dealing with the complex drug-drug interactions: towards mechanistic models.Development and Characterization of Novel and Selective Inhibitors of Cytochrome P450 CYP26A1, the Human Liver Retinoic Acid Hydroxylase.Functional polymer-dependent 3D culture accelerates the differentiation of HepaRG cells into mature hepatocytes.Inhibition of the all-trans Retinoic Acid (atRA) Hydroxylases CYP26A1 and CYP26B1 Results in Dynamic, Tissue-Specific Changes in Endogenous atRA Signaling.In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation.Predicting nonlinear pharmacokinetics of omeprazole enantiomers and racemic drug using physiologically based pharmacokinetic modeling and simulation: application to predict drug/genetic interactions.Stereoselective Metabolism of Bupropion to OH-bupropion, Threohydrobupropion, Erythrohydrobupropion, and 4'-OH-bupropion in vitro.Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.Online monitoring of hepatic rat metabolism by coupling a liver biochip and a mass spectrometer.Physiologically Based Pharmacokinetic Model of All-trans-Retinoic Acid with Application to Cancer Populations and Drug Interactions.Hepatic Transport of 25-Hydroxyvitamin D3 Conjugates: A Mechanism of 25-Hydroxyvitamin D3 Delivery to the Intestinal Tract.Effect of Omeprazole and Dextromethorphan on the Urinary Metabolic Ratio of Flurbiprofen.
P2860
Q26825569-0F2E1BA3-A9DF-4267-8DA0-4390014202B1Q28307990-A265016D-F08C-48A1-B8A3-05D03F6FB265Q28395323-D89F2FE2-E293-4627-A87D-7E4242FEAD5AQ31123470-17B3E85F-63E7-463F-B755-2E2B910EC8F3Q34542725-DD224779-9EC3-44B7-89E6-3F912EA998FDQ35600241-FB5DAB51-4C83-4555-B3AD-A9B7B9C4276AQ35897778-BFBA8E6E-D37D-4532-8601-BF418E0983C0Q36643041-B8E67ED9-B20A-47AB-BA6A-10E180F44CEDQ36852503-AA409533-28AD-447C-9A2D-B9EDABE43AB9Q37587285-5CADC672-4D49-4D80-84E7-C9CE7C6057CCQ38302225-A169C03A-3A6D-4059-A9AE-BA7962C58328Q38790863-FF9CD56A-8668-4CED-9ACC-C9658BB75D63Q38807048-35893B6E-58EF-47C1-BC98-D520BDF3D145Q38818104-0E760A08-DB3E-4D54-86E8-F4961FD8D91CQ39194285-E9035CC8-99C1-47DB-98F6-00A8A0C363F8Q39240124-D01D972F-3C7C-4DB8-9E96-A6B34000914AQ39519725-3CEDAE25-3055-48CC-B45E-AA876D47F9D0Q41174078-21D53D95-B8D6-4F1B-8EA2-BBC9884B3600Q41737190-77C21E0D-4681-467B-96DA-21C11B996503Q48004624-53EFC9FF-DC41-430A-B821-C3F22A1A77C9Q51105253-87E4B365-DF92-44E8-AFD1-6FAE9443F662Q52691643-F02D120F-6DB3-494B-A63D-A3A09BB96CF9Q52860025-D64197D6-422B-4874-984B-7233A31343A5
P2860
Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Inhibition of CYP2C19 and CYP3 ...... tion to drug-drug interactions
@ast
Inhibition of CYP2C19 and CYP3 ...... tion to drug-drug interactions
@en
Inhibition of CYP2C19 and CYP3 ...... tion to drug-drug interactions
@nl
type
label
Inhibition of CYP2C19 and CYP3 ...... tion to drug-drug interactions
@ast
Inhibition of CYP2C19 and CYP3 ...... tion to drug-drug interactions
@en
Inhibition of CYP2C19 and CYP3 ...... tion to drug-drug interactions
@nl
prefLabel
Inhibition of CYP2C19 and CYP3 ...... tion to drug-drug interactions
@ast
Inhibition of CYP2C19 and CYP3 ...... tion to drug-drug interactions
@en
Inhibition of CYP2C19 and CYP3 ...... tion to drug-drug interactions
@nl
P2093
P2860
P356
P1476
Inhibition of CYP2C19 and CYP3 ...... tion to drug-drug interactions
@en
P2093
Connie Davis
Jennifer E Sager
Justin D Lutz
Nina Isoherranen
Yoshiyuki Shirasaka
P2860
P304
P356
10.1124/DMD.113.051722
P407
P577
2013-07-01T00:00:00Z